Actyon Discovery, Inc.
Staking Claims in Intellectual Property Free Drug Space
–
We build Ultra Large Reaction Spaces.
Each Ultra Large Reaction Space (ULRS) contains billions of newly conceived molecules with chemical features (synthons) that are known to elicit biological activity at our desired drug target.
For each drug discovery project, we select building blocks containing desirable bioactive synthon groups. We combine these selected building blocks with compatible chemical reactions to forecast all potential synthetic end products which may be created.
Typical ULRS Project Size
50,000+
Building Blocks
10+
Reactions
6+
Billion Products
Each ULRS is designed to contain only synthetically accessible* molecules built on new and unprecedented chemical scaffolds from previously unexplored chemistry.
This strategy enables us to rapidly explore and identify bioactive compounds from intellectual property free regions (IP-Free Chemistry) in these newly conceived reaction spaces.
* Synthetic accessibility is assessed using the Synthetically Accessible Virtual Inventory (SAVI) approach developed and successfully applied by Dr. Marc Nicklaus’ Team at the US National Cancer Institute. For more information on SAVI: https://doi.org/10.1038/s41597-020-00727-4
We chart IP-Free chemical space using novel plain ring systems.
The Actyon plain ring systems approach enables us to identify regions of ultra large reaction spaces that are IP Free.
By IP Free we mean the molecules, and more importantly their structural scaffolds based on plain ring systems, that have not been reported in public sources and that are not implicated in existing global patents.
In the accompanying table, examples of novel plain ring systems are shown on the left, and examples of IP Free molecules are on the right.
Plain ping systems provide a strategy for broad intellectual property claims around new compounds in comparison to the narrower variations defined by Murcko Scaffolds and Markush definitions.
Combined with SAVI based synthesis routes for specific compounds, the plain ring system approach provides a basis for strong composition-of-matter patents.
Novel Plain Ring
Example Molecule
–
Founders & Key Advisors
Scott Hutton
Co-Founder / Chief Executive Officer
Lutz Weber, Ph.D.
Co-Founder / Chief Technology Officer
Marc Nicklaus, Ph.D.
Key Scientific Advisor – Synthetic Accessibility
Advisory Board
Hans-Joachim Böhm, Ph.D.
Scientific Advisory Board Member
Peter Ertl, Ph.D.
Scientific Advisory Board Member
Rick Burgoon
Key Business Advisor / Corporate Secretary
About Us
Actyon Discovery, Inc. (“Actyon”) is a seed-stage digital drug discovery company focused on the design, validation, and delivery of novel scaffold based small molecule drug candidates to drug development partners.
Staking Claims in IP-Free Drug SpaceTM: Actyon discovers intellectual property free (IP-Free) novel drug scaffolds from unexplored chemistry spaces.
The Actyon drug discovery approach employs the creation of ultra-large virtual libraries containing billions of newly discovered synthetically accessible drug-like molecules. These unexplored chemistry spaces are analyzed for novel chemistry classes based on innovative IP-free scaffolds. AI based tools are used to identify molecules likely to interact with selected drug targets. These high priority molecules are synthesized by 3rd party partners based on synthetic guidelines from the Actyon platform. Compound bioactivity is validated through 3rd party assay service partners.
Actyon’s drug candidates will be protected by strong composition of matter patents and delivered at a fraction of the time and cost of in-house drug discovery and development programs.
We have established 3 proof-of-concept novel Drug Lead Programs available for license through Actyon.
These include:
- Mpro SARS-Cov2 inhibitors
- Ras-SOS1 interaction inhibitors
- New Clozapine alternatives